Articles On Actinogen Medical (ASX:ACW)

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Late-stage trial in Alzheimer’s opens 10 sites in US, with results due in 2025 a...

The ASX200 closed down 0.03% at 8,423 points. Gold rose after China’s central bank added bullion to its reserves in November, resuming a key pillar of support for the precious metal. Bullion climbed by 0.5% to US$2,640. Energy was the...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

For years, people dreamed that science would one day create a pill to cure all ills.  Today, one small pill may not cure everything, but it holds the potential to transform cognitive medicine by addressing debilitating conditions like de...

Amid improving sector sentiment, Actinogen says its Alzheimer’s trial is off to a flier Telix shares start trading on the Nasdaq tonight More of the Trump-edelic effect? Tryptamine shares are on a roll   Actinogen Medical (ASX:ACW) report...

Actinogen Medical Ltd (ASX:ACW) has received a $9 million R&D (research and development) tax incentive rebate for the 2024 fiscal year, based on clinical tests of its lead compound Xanamem – a prospective therapy for Alzheimer’s Disease...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Emvision expects to release trial results for its Emu stroke-detection device in November Syntara’s rare blood cancer program gathers pace Actinogen says 25 patients have been treated in its 200-candidate Alzheimer’s disease study   Quart...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Research reports on ASX-listed companies, to download in full. **** -Actinogen Medic...

Cancer drug developer Chimeric Therapeutics eyes minimum $5 million raising ‘The next Telix’, Clarity gets FDA go-ahead for prostate cancer trial LTR Pharma fleshes out erectile dysfunction trial results   Cancer cell therapy house Chimer...

If you have retirement on the horizon, then now could be the time to start thinking about building an investment portfolio that is appropriate for this stage of your life. But what sort of ASX shares would be suitable for someone that is re...

S&P/ASX 200 Index (ASX: XJO) tech stock NextDC Ltd (ASX: NXT) has had a great run over the past year. On Thursday, shares in the data centre operator and developer closed 2.44% higher, trading for $17.64 apiece. That sees the Next...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Renewed optimism lifted the S&P/ASX 200 by 3% in September, closing at a record 8,239.20 points S&P Dow Jones Indices said small cap companies outperformed in September, with the materials sector rebounding 13%  Mithril Silver and...

Investors that are on the lookout for ASX tech shares to buy might want to check out the two in this article. That's because analysts at Goldman Sachs have recently tipped them as buys. Let's see why the broker is bullish on them: Hansen T...

Wanting exposure to the retail sector? Then it could pay to listen to what analysts at Bell Potter are saying. The broker has just named two ASX retail stocks to buy and two to hold. Let's see what the broker is recommending. What is the br...

Actinogen Medical (ASX:ACW) is developing a promising oral treatment for Alzheimer’s and depression and is accelerating clinical trials with new capital. CEO Steven Gourlay, joins The Market Online to discuss the company’s development....

Analysts at Morgans have been busy looking back at last month's earnings season and have identified a number of ASX shares that they are describing as "key picks". Let's now take a look at two that the broker is tipping as buys this week. T...

There are some wonderful S&P/ASX All Ordinaries Index (ASX: XAO) shares that could be worth owning. The biggest ASX shares may get the most attention, but the businesses with the most growth potential are significantly smaller than s...

Aussie electronics store JB H-Fi Ltd (ASX: JBH) has been one of the best-performing ASX retail stocks to own this year. While competitors like Harvey Norman Holdings Limited (ASX: HVN) and Kogan.com Ltd (ASX: KGN) have struggled in 2024, JB...

Recent updates highlight significant strides in the biopharmaceutical sector. Paradigm Biopharmaceuticals Ltd has received FDA feedback on its Phase III osteoarthritis study. Actinogen Medical Ltd has secured funding for its Alzheimer’s tri...

Health Check (briefly called Alive and Kicking before we grew tired of the Simple Minds tune running through our noggins) is renowned biotech journo Tim Boreham’s NEW daily wrap covering morning movers and shakers of note in the ASX Healthc...

The S&P/ASX 200 Index (ASX: XJO) is having a subdued session on Wednesday. At the time of writing, the benchmark index is down slightly to 8,140 points. Four ASX shares that are falling more than most today are listed below. Here's wh...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin World Overnight SPI Overnight 8116.00 – 34.00 – 0.42% S&P ASX 200 8140.90...

  ASX hits all-time high before retreating slightly Gold miners surge as prices near record high Hong Kong falls on weak China data; Yen rises     The ASX briefly hit an all-time high on Monday before paring gains. At the close of the da...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

The S&P/ASX 200 Information Technology sector rose ~8% in August, despite a volatile month for global markets Global X said the Nasdaq had mixed performance driven by a combination of positive and negative factors  Wisetech Global rose...

S&P/ASX 200 recovers from heavy volatility early in the month to finish up 0.47% in August S&P Dow Jones Indices said mid-caps led the gains putting them ahead of large and small caps YTD Larvotto Resources rose on the back of Chin...

This week’s Bulls N’ Bears Runner of the Week is … MC Mining. The South African-focused coal producer inked a US$90 million cash injection, while Actinogen Medical, Kalina Power and Felix Gold also ran hard.

Aussie shares rose on Fed rate cut hopes Kelsian plunged, while Kalina, Actinogen and Kogan surged Uranium stocks gained on Kazatomprom’s production guidance cut   Aussie shares have kicked off the week strongly, buoyed by US Fed Reserve...

Australian biotechnology company Actinogen Medical (ASX: ACW) has received further positive analysis from studies of its Xanamem treatment for symptoms of depression. The consistent benefits observed in the XanaCIDD phase 2a depression tria...

Actinogen doubled on positive Phase 2a results for Xanamem Xanamem’s durability leads to a Phase 2b Alzheimer’s trial PharmAust’s monepantel showed promising ALS results   Actinogen doubles on promising Phase 2a trial data Actinogen Medic...

  Actinogen Medical (ASX:ACW) has announced positive results from its XanaCIDD phase 2a depression trial. Xanamem, the company's drug candidate, demonstrated consistent benefits in reducing depression symptoms across multiple endpoints, sug...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

Actinogen (ASX:ACW) has reported success in using its novel antidepressant Xanamem to mitigate the symptoms of major depression based on a daily 10mg dose. Shares in the microcap stock soared 30% to 3.1cps on a volume of 15M+ shares in...

ASX health stocks rise 0.8% past five days as broader market lifts 3.7%  Morgans says ProMedicus ‘produced yet another record result’ with net profit of $82.8m in FY24  CSL falls on FY24 results but Morgans still bullish on ASX’s largest h...

While the S&P/ASX 200 Index (ASX: XJO) is enjoying a positive day, with the benchmark index up 0.5% to 7,866.5 points as of midday Wednesday, several ASX shares are struggling and failing to keep pace with the broader market gains. Let’...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a decent gain. At the time of writing, the benchmark index is up 0.5% to 7,866.5 points. Four ASX shares that are failing to follow the market's lead today are...

Actinogen Medical (ASX:ACW) recently announced results from its XanaCIDD Phase 2a trials, which demonstrated the drug’s significant clinical and statistical benefits over a placebo in treating depression. CEO Steve Gourlay emphasised it...

ASX rises circa 0.5pc Consumer stocks in focus this week SGQ and PHX lead small caps   Aussie stocks have closed higher on Monday as IT and retail stocks added strength to sentiment. The S&P/ASX200 closed higher, gaining 36.00 points...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another solid gain. At the time of writing, the benchmark index is up 0.5% to 7,816.4 points. Four ASX shares that have failed to follow the market higher today...

Tryptamine’s psilocybin trial indicates potential for treating fibromyalgia Actinogen says Xanamem eases depression but misses cognitive goals PYC reports vision gains using experimental eye drug   Tryptamine’s Phase 2a trial shows promis...

It has been a disastrous start to the week for Actinogen Medical Ltd (ASX: ACW) shares. In morning trade, the ASX healthcare stock was down as much as 67% to 2.5 cents. The neurological and neuropsychiatric diseases focused biotechnology co...

Good morning, and welcome to Stockhead’s Top 10 at around 11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading...

The ASX dropped, dragged down by Real Estate and Mining stocks Qantas cuts former CEO’s compensation by $9.3m Fears of a US recession are growing, with the Sahm Rule signalling potential trouble   A selloff in Real Estate and Mining stock...

An imminent trial result may validate whether Actinogen’s Xanamem is ‘the next Ozempic’. Originally developed for diabetes and embraced as a weight loss drug by the beautiful people, Ozempic is also showing promise in the $US4.8 billion-a-y...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

ASX health stocks rise 2% in past five days as broader markets lift 0.6% Morgans upgrades disinfectant device maker Nanosonics after positive trading update  Neuren receives rare paediatric disease designation from FDA for NNZ-2591 in Phel...